Department of Medical Oncology/Hematology, Orlando Health Cancer Institute, Orlando, Florida, United States
Original Article
Does Erlotinib Restore Chemosensitivity to Chemotherapy in Pancreatic Cancer? A Retrospective Analysis
Author(s): Muhammad Wasif Saif, Jyothi Jose and Jeffrey Chi
Background Erlotinib, an Epidermal Growth Factor Receptor (EGFR) inhibitor, in combination with gemcitabine was approved in 2005 as 1st-line therapy for patients with Advanced Pancreatic Cancer (APC). In the second line setting, erlotinib as monotherapy and in combination regimens was evaluated in small studies with limited benefit. We previously published a case series documenting a potential benefit of adding erlotinib to chemotherapy at the time of Progression of Disease (PoD) in patients with APC. Patients and Methods Here, we update our cohort of patients to a total of 27 diagnosed with APC who received erlotinib upon PoD to prior chemotherapy regimens. Final analysis of this cohort showed a PFS of 4.0 months (range: 2 - 11) with median OS of 10.1 months (range: 7 - 16). CA19- 9 levels declined by greater than 50% in 23% of the patients, by 25 - .. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 